CELC
Celcuity
October 16, 2026 · market open
- Rarity
- 1.72
- Peak move
- −11.09%
- Float cap
- $2.2B
Celcuity is a clinical-stage biotechnology company based in Minneapolis developing targeted therapies for solid tumors, chiefly in advanced breast and prostate cancer. Its lead candidate, gedatolisib, licensed from Pfizer, inhibits PI3K and mTOR in patients with HR-positive, HER2-negative metastatic disease. It also offers the CELsignia platform, which analyzes living tumor cells to identify patients likely to respond to targeted drugs.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
1 event · 0 from SEC or newswire · 0 timed with the moveanalyst_ratingZacks Research downgraded Celcuity (CELC) from hold to strong sell and added it to the Zacks Rank #5 (Strong Sell) list on October 14, 2026, citing a 15.3% downward revision to the Zacks Consensus Estimate for current-year earnings over the prior 60 days.